Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT04211935 |
Other study ID # |
19-2794 |
Secondary ID |
|
Status |
Recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
May 27, 2020 |
Est. completion date |
June 2024 |
Study information
Verified date |
November 2023 |
Source |
University of Colorado, Denver |
Contact |
Jose L Diaz-Miron, MD |
Phone |
720-777-6571 |
Email |
jose.diaz-miron[@]childrenscolorado.org |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Pectus excavatum is the most common chest wall deformity in children, accounting for 90% of
all congenital chest wall deformities. It occurs in one to eight per 1000 live births. The
severity of the pectus deformity may become more noticeable during pubertal growth spurs and
repair is therefore usually performed in the teenage years. A common operative procedure to
repair a pectus deformity is the minimally invasive repair of pectus excavatum (MIRPE). The
MIRPE involves the substernal placement of a contoured metal bar secured to the lateral
aspect of the ribs. This metal bar allows for correction of the concave deformity by applying
constant outward pressure to the underside of the sternum. Although the cosmetic results are
excellent, patients do report significant pain from the constant pressure exerted on the
chest wall from the metal bar. Pain management approaches tend to differ on both the provider
and institutional level. There is a lack of evidence regarding which postoperative analgesia
method is best. To address this research gap, this proposal aims to conduct a randomized
controlled trail using the three most commonly used methods; 1) patient controlled analgesia
(PCA); 2) erector spinae blocks (ESB) with continuous infusion pumps; and 3) video-assisted
intercostal nerve cryoablation (INC).
Description:
Pectus excavatum deformity is a common condition in a pediatric surgical practice. While
MIRPE provides excellent cosmetic results and is associated with shorter operative time and
lower intraoperative blood loss, the immediate correction of the concave deformity with a
metal bar places patients in a difficult pain control situation. While multiple postoperative
analgesia modalities have been studied, there is still a need for a large, prospective,
randomized trial that is appropriately powered to evaluate the best pain control modality
after MIRPE. Of the clinically appropriate interventions, ESB and INC have been shown to have
comparable LOS after the operation, especially when employed as part of an enhanced recovery
pathway (ERP) bundle. Comparing these newer analgesia modalities to the more established PCA
approach may help identify the most effective postoperative pain control approach that
maximizes the safety profile while minimizing the use of narcotic pain medications after
MIRPE.
The investigators propose a prospective randomized trial evaluating the effectiveness of INC,
PCA and ESB with continuous local anesthetic infusion via a pain pump delivery system. All
groups will follow a multimodal enhanced recovery pathway. Groups will different only in the
use of INC, PCA, or ESB.
Since previous studies have reported similarly short LOS for both ESB and INC, but no
prospective, direct comparisons of these techniques have been done, we believe comparing
these two groups to the more established PCA modality will further advance the field of post
MIRPE pain management by providing precise estimates of length of stay (LOS), hospital
resource utilization, and other important outcomes that have not received sufficient
attention including pain, quality of life, resumption of activities of daily living, and a
rigorous survey for potential adverse outcomes. The investigators specifically hypothesize
that because of the long-term analgesia of up to 2-3 months, the INC group may experience not
only shorter LOS but decreased narcotic use than the ESB and PCA groups, and also improved
quality of life, with fewer encounters in the postoperative period (30 days) for pain related
concerns.